Abstract The outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 has had a significant impact worldwide. No effective prophylaxis or treatment for SARS is available up to now. Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for SARS-associated coronavirus (SARS-CoV). By expressing a U6 promoter-driven small interfering RNA containing sequences homologous to part of ACE2 mRNA, we successfully silenced ACE2 expression in Vero E6 cells. By detecting negative strand SARS-CoV RNA and measuring RNA copy numbers of SARS-CoV by real-time reverse transcription polymerase chain reaction (RT-PCR), we demonstrated that SARS-CoV infection was reduced in the ACE2-silenced cell lines. These findings support the involvement of ACE2 in SARS-CoV infections and provide a basis for further studies on potential use of siRNA targeting ACE2 as a preventive or therapeutic strategy for SARS.
Introduction
The outbreak of severe acute respiratory syndrome (SARS) in 2002-2003 affected over 8,000 individuals and was responsible for almost 800 deaths (WHO, 2004) . It also caused significant psychological and economic impacts worldwide [1, 2] . Although the SARS epidemic was stopped in mid-2003, the potential threat of SARS will remain high as long as no effective prevention or treatment for SARS is available.
Spike proteins of SARS-associated coronaviruses (SARSCoV) interact with cellular receptors to mediate the infection of their target cells [3] . By using immunoprecipitation, Li et al. identified a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), as the cellular receptor for SARS-CoV [4] . ACE2 is expressed mainly in the heart and kidneys but is also found in the bronchi and lungs [5, 6] , where the major pathology of SARS resides.
RNA interference (RNAi) is a cellular process wherein short, double-stranded RNAs called small interfering RNAs (siRNAs) activate ribonucleases to target homologous mRNA [7, 8] . It has been used as a powerful tool for gene silencing. RNAi is also regarded as an antiviral strategy used by plants and probably other organisms [9] . Moreover, applications of RNAi technologies in the treatment or prevention of infectious diseases are being tested extensively.
The African green monkey kidney cell line Vero E6 expresses ACE2 and permits the replication of SARS-CoV [10] . In this study, we tested the hypothesis that RNAi technology can effectively eliminate ACE2, the cellular receptor for SARS-CoV, from Vero E6 cells and block SARS-CoV infections in these cells. the AAN 19 TT pattern. These sequences were all analyzed by BLAST search of the GenBank database. Sequences with more than 16-17 contiguous base pairs of homology to other coding sequences were excluded. Two mutually complementary 64 oligonucleotides encoding small hairpin sequences targeting position 200-222 of human ACE2 mRNA (5′-GATCCGCCACGAAGCCGAAGACCTGTT CAAGAGA CAGGTCTTCGGCTTCGTGGTTTTTTG GAAA-3′ and 5′-AGCTTTTCCAAAAAACCACGAAGC C G A A G A C C T G T C T C T T G A A C A G G T C T T C G G CTTCGTGGCG-3′) were synthesized, annealed, and ligated to the BamHI/HindIII sites of pSilencer 2.1-U6 neo to make pSilencer-ACE2. The inserted sequences were confirmed by direct sequencing.
Establishment of ACE2-silenced stable cell lines
The African green monkey kidney cell Vero E6 (CRL-1587) was purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in minimal essential medium with Earle's balance salts (EMEM, JRH Biosciences, Lenexa, KS, USA) with 10% fetal bovine serum (FBS, Biological Industries, Kibbutz Bet Haemek, Israel). Vero E6 cells (3×10 5 cells/well) were seeded into 6-well plates in EMEM with 10% fetal calf serum 1 day before transfection in order to get a 70% confluence at transfection. pSilencer-ACE2 plasmids were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with a ratio of 4 ug DNA mix to 10 ul Lipofectamine 2000 per well, according to the manufacturer's instructions. Transfection of the same plasmids was repeated once 48 h later. The cells were subcultured 24 h after the transfections, and then every 2-3 days in complete medium containing 2 mg/ml G418 (Sigma, St. Louis, MO, USA). The concentration of G418 was reduced to 1 mg/ml 14 days later. The cells were then diluted and single colonies were picked for further experiments.
SARS virus infection
The SARS-CoV strain TW1 [2] , which was isolated from a confirmed SARS patient in the National Taiwan University Hospital, was used for infection. 
Flow cytometry analysis
Vero E6 and other cells were trypsinized and washed with 1% bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) in phosphate-buffered saline (PBS). Aliquots of 10 6 cells were incubated in 100 ul PBS with or without 5 ug of ACE2 antibody for 60 min at 4°C. The cells were washed with 1% BSA/PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat secondary antibody for 30 min at 4°C. The cells were then fixed with 2% formaldehyde and stored at 4°C until analysis. Data were acquired by the BD FACSCalibur system and analysis by Cell Quest (BD Bioscience, Franklin Lakes, NJ, USA).
Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Supernatants of cell cultures infected with the SARS-CoV were used for RNA extraction according to the mini spin protocol of the QIAamp virus RNA mini kit (Qiagen, Hilden, Germany). The extracted RNA was eluted in 50 µl RNase-free water, treated with deoxyribonuclease I (Life Technologies, Carlsbad, CA, USA) to digest genomic DNA, and stored at −80°C before use. Quantitative RT-PCR for SARS-CoV RNA was done by using the RealArt HPA-coronavirus LC RT-PCR Reagent (Artus Biotech, Hamburg, Germany) on a LightCycler instrument from Roche Diagnostics (Mannheim, Germany). Serial dilutions of the SARS-CoV stock were used as a standard.
Real-time RT-PCR was also done to quantify the amount of ACE2 mRNA. A primer pair that extends over two exons of ACE2 (1528-AAAGTGGTGGGAGATGAAGC and 1572-GTTTCATCATGGGGCACA) was used to amplify an amplicon of 63 nucleotides. A fluorophore and quencher dual-labeled probe (Human #77 from Exiqon, Vedbaek, Denmark) was used on the Roche LightCycler (Roche Diagnostics, Mannheim, Germany). GADPH mRNA was also amplified as an internal control and used for normalization with the primer pair CTCATGACCACAG TCCATGC (left) and CCCTGTTGCTGTAGCCAAAT (right).
Negative strand-specific RT-PCR Negative strand-specific reverse transcription for SARSCoV RNA was carried out with 0.1 ug of total RNA, 20 units of AMV reverse transcriptase (Roche Diagnostics, Indianapolis, IN, USA), and the sense primer (BNIoutS2: ATGAATTACCAAGTCAATGGTTAC) [11] at 42°C for 60 min. PCR with the primer pair ATGAATTACCAAGT CAATGGTTAC (BNIoutS2) and CATAACCAG TCGGTACAGCTA (BNIoutAs) [11] was then performed with universal cycle conditions (10 min at 95°C, 45 cycles of 10 s at 95°C, 10 s at 55°C, and 5 s at 72°C) on a LightCycler (Roche Diagnostics, Penzberg, Germany). The products were visualized by ethidium bromide staining after separating by 2-3% agarose gel electrophoresis. Again, GADPH mRNA was also amplified by PCR as an internal control with the primer pair CTCATGACCACAGTC CATGC (left) and CCCTGTTGCTGTAGCCAAAT (right). (Fig. 2b) , with significantly reduced ACE2 expression. Western blotting showed different degrees of ACE2 expressions in various clones. Clones A4 and C4 both had >99% reductions in ACE2 expressions by Western blotting and were used for further experiments (Fig. 1a) . Quantitative RT-PCR also revealed 96.2-96.7% reductions in ACE2 mRNA in both clones (Fig. 1b) . Flow cytometry further The numbers over the bars denote relative copy numbers of ACE2 mRNA normalized by GAPDH copy numbers. Clones A4 and C4 showed less than 4% of ACE2 mRNA left in comparison to the original Vero E6 cells. c Expressions of ACE2 in Vero E6 and clone A4 were determined by flow cytometry. The thin dotted line represents unstained control. ACE2 expression was hardly detectable in the majority of A4 cells confirmed that ACE2 expression was significantly reduced in clone A4 (Fig. 1c) . Repeated Western blotting for ACE2 expression after removal of G418 proved that ACE2 of these cells were stably silenced (data not shown).
Results

ACE2 expression was silenced in
Vero E6 cells by siRNA After two consecutive Lipofectamine transfections of pSilencer-ACE2, Vero E6 cells grew normally
Replication of SARS-CoV was blocked in ACE2-silenced cells
Infections of SARS-CoV were done for Vero E6, A4, and C4 cells in a parallel fashion. Figure 2a and b show morphology of Vero E6 and A4 cells, respectively. Vero E6 showed good susceptibility to SARS-CoV. Almost all Vero E6 cells rounded up and died 16 h after inoculation (Fig. 2d) . On the other hand, A4 and C4 cells remained grossly healthy at 16 h post-inoculation, except for a few foci of typical cytopathic effects (Fig. 2e) .
By using a negative strand RNA-specific primer, the cDNA of the negative strand RNA of SARS-CoV RNA was synthesized and amplified. A product of 189 base pairs in size was detected in the Vero E6 but not in A4 or C4 cells (Fig. 3) . SARS-CoV is a positive-stranded RNA virus. Replication of SARS-CoV required synthesis of a negative strand of SARS-CoV. Inability to detect a negative strand RNA in ACE2-silenced A4 and C4 cells confirmed the lack of SARS-CoV replication in these cells.
Production of SARS-CoV was compared between Vero E6 and A4 cells by determining SARS-CoV RNA copy numbers with qRT-PCR at various time points after inoculation (Fig. 4) . With the inoculation dose of 1 MOI, SARS-CoV viral loads increased robustly to the same plateau in both Vero E6 and A4 cells. (Fig. 4a) . When the inoculation dose decreased, the velocity of viral amplification also decreased. At inoculation doses of 10 -1 or 10
MOI, SARS-CoV replication was significantly delayed in A4 cells. Lower viral loads were demonstrated in A4 than in Vero E6 at 24-48 h post-infection. However, the viral loads reached comparable levels in both cells at 72 h postinfection (Fig. 4b,c) . When the inoculation dose was further decreased to 10 -3 MOI, the virus did not replicate in A4 Fig. 3 Negative strand of SARS-CoV RNA was detected in Vero E6 cells but not in ACE2-silenced A4 or C4 cells. RT-PCR using negative strand SARS-CoV RNA-specific primer for was done at 0 and 24 h after inoculation for Vero E6, A4, and C4 cells. A positive result for negative strand RNA of SARS-CoV was shown for Vero E6 cells at 24 h after inoculation. A4 and C4 cells whose ACE2 had been silenced showed no negative strand of SARS-CoV. GAPDH was amplified as an internal control cells up to 72 h post-infection (Fig. 4d) . The experiment was repeated twice with varied viral load readout but the same trends. The results shown in Fig. 4 were representative of the two independent experiments.
Discussion
The discovery of RNAi, together with development of methods for their generation and delivery, has led to potential application of RNAi as a novel antiviral approach. Reports regarding inhibition of SARS-CoV by RNAi are accumulating [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and reviewed elsewhere [22, 23] . Using viral receptors or coreceptors as targets in inhibiting viral replication has also been tested for certain viruses, such as human immunodeficiency virus (HIV) [24, 25] . To our knowledge, however, this is the first study to test the feasibility of blocking SARS-CoV infections by siRNA targeting its cellular receptor, ACE2.
In several earlier studies testing the susceptibility of various permanent and primary eukaryotic cell lines to SARS-CoV, ACE2 mRNA could be detected in all of the susceptible cell lines and its abundance correlated with SARS-CoV susceptibility [26] [27] [28] . On the other hand, refractory cell lines were made permissive to SARS-CoV by the exogenous expression of ACE2 [29] . Our study extended these observations by showing that SARS-CoV susceptibility was reduced in Vero E6 cells as the ACE2 mRNA was reduced by siRNA.
Although successful silencing of ACE2 and reduction of susceptibility to SARS-CoV were shown in the current study, obstacles exist in clinical usage of RNAi-mediated ACE2 silencing as a preventive or therapeutic modality for SARS-CoV infections. The blocking effects of ACE2 silencing appeared to be modest. In our experiments with an inoculation dose of 10 -1 to 10 -2 MOI, viral loads reached nearly normal levels 72 h post-inoculation (Fig. 4b,c) , suggesting as low as 4% of ACE2 expression ( Fig. 1 ) is sufficient to support entry of SARS-CoV particles adequate to produce equivalent viral loads at 72 h. The presence of some other cellular receptor(s) for SARS-CoV is another possible explanation for the failure in blocking SARS-CoV replication at higher inoculations. CD209L was reported to be a minor receptor for SARS-CoV and has proved the possibility [30] . The efficacy of ACE2 silencing could theoretically be enhanced by choosing different targets, or using a "multiplehit" approach by incorporating several siRNAs targeting various RNA sequences of SARS-CoV and its receptor(s) at the same time might be useful. Synergistic effects of more than one siRNA targeting different genes of SARS-CoV have been observed [31] . Besides, a recent study showed that interleukin (IL)-4 and interferon (IFN)-gamma can downregulate ACE2 expression on the cell surface and inhibit SARS-CoV replication [32] . "Cocktail" approaches by coadministration of RNAi and non-RNAi strategies to suppress ACE2 expression might maximize clinical effectiveness and hence have potential therapeutic applications. Another concern about translating the current results to a clinically relevant context is that ACE2 was reported to be an essential regulator of cardiac function [33, 34] . ACE2 knockout mice showed cardiac dysfunction [34] . Selective elimination of ACE2 in organs vulnerable to SARS-CoV has never been tested in vivo and could possibly lead to unexpected consequences.
In summary, through siRNA technology, we have specifically silenced ACE2, the cellular receptor for SARS-CoV, in Vero E6 cells. Replication of SARS-CoV was reduced in these ACE2-silenced cells. The hypothesis that eliminating ACE2 can reduce or block SARS-CoV infections was proved to be true. However, considering the modest effect observed and concerns raised above, applying siRNA technology for SARS prevention or therapy requires further efforts.
